Phenotypic screening of the prestwick library for treatment of parkinson's tremor symptoms using a humanized quantitative systems pharmacology platform

Journal of Parkinson's Disease

Volumn 3, Issue 4, 2013, Pages 569-580

  Spiros, Athan ^a   Roberts, Patrick ^a,b   Geerts, Hugo ^a,c,d  

^a In Silico Biosciences   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Drug repurposing; Parkinson's disease; Systems pharmacology; Tremor

Indexed keywords

ARIPIPRAZOLE; CARBON 11; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; FIPAMEZOLE; LEVODOPA; MAPROTILINE; METERGOLINE; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PHENTOLAMINE; PROPRANOLOL; QUETIAPINE; SEROTONIN AGONIST; SETOPERONE; TRAZODONE; ZIPRASIDONE;

ARTICLE; CLINICAL STUDY; COMPUTER MODEL; COMPUTER SIMULATION; COMPUTER SYSTEM; CORPUS STRIATUM; COST; DEPRESSION; DROWSINESS; DRUG DEVELOPMENT; DRUG PENETRATION; DRUG REPOSITIONING; DRUG SCREENING; DRUG STRUCTURE; ELECTROPHYSIOLOGY; HUMAN; HYPOTENSION; MIGRAINE; MOLECULAR LIBRARY; MOOD DISORDER; MOTOR CORTEX; MOTOR DYSFUNCTION; NERVE CELL NETWORK; NEUROPHYSIOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARKINSONISM; PREDICTION; PRESTWICK LIBRARY; PRIORITY JOURNAL; QUANTITATIVE SYSTEMS PHARMACOLOGY PLATFORM; SOMNOLENCE; TIME; TREMOR; XEROSTOMIA;

DRUG REPURPOSING; PARKINSON'S DISEASE; SYSTEMS PHARMACOLOGY; TREMOR;

ANIMALS; CENTRAL NERVOUS SYSTEM AGENTS; DRUG REPOSITIONING; HUMANS; PARKINSON DISEASE; TREMOR;

EID: 84898728908     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-130211     Document Type: Article

References (58)

1. Linazasoro G (2004) Recent failures of new potential symptomatic treatments for Parkinson's disease: Causes and solutions. Mov Disord, 19, 743-754.
2. Lewitt PA (2008) Levodopa for the treatment of Parkinson's disease. N Engl J Med, 359, 2468-2476.
3. Wirshing WC (2001) Movement disorders associated with neuroleptic treatment. J Clin Psychiatry, 62(Suppl 21), 15-18.
4. Burgyone K, Aduri K, Ananth J, & Parameswaran S (2004) The use of antiparkinsonian agents in the management of drug-induced extrapyramidal symptoms. Curr Pharm Des, 10, 2239-2248.
5. Gerlach M, & Riederer P (1996) Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man. J Neural Transm, 103, 987-1041.
6. Smith GA, Isacson O, & Dunnett SB (2012) The search for genetic mouse models of prodromal Parkinson's disease. Exp Neurol, 237, 267-273.
7. Spiros A, Roberts P,&GeertsH(2012)Aquantitative systems pharmacology computer model for schizophrenia efficacy and extrapyramidal side effects. Drug Dev. Res, 73(4), 1098-1109.
8. Geerts H, Spiros A, Roberts P, Twyman R, Alphs L, & Grace AA(2012) Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response. PLoS ONE, 7, e49732.
9. Pedrosa DJ, Reck C, Florin E, PaulsKA,MaaroufM,Wojtecki L, Dafsari HS, Sturm V, Schnitzler A, Fink GR, & Timmermann L (2012) Essential tremor and tremor in Parkinson's disease are associated with distinct ?tremor clusters' in the ventral thalamus. Exp Neurol, 237, 435-443.
10. Marjama-Lyons J, & Koller W (2000) Tremor-predominant Parkinson's disease. Approaches to treatment. Drugs Aging 16, 273-278.
11. Spieker S, Eisebitt R, Breit S, Przuntek H, Muller D, Klockgether T, & Dichgans J (1999) Tremorlytic activity of budipine in Parkinson's disease. Clin Neuropharmacol, 22, 115-119.
12. Fernandez HH (2012) Updates in the medical management of Parkinson disease. Cleve Clin J Med, 79, 28-35.
13. Friedman JH, Koller WC, Lannon MC, Busenbark K, Swanson-Hyland E, & Smith D (1997) Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Neurology, 48, 1077-1081.
14. Fasano A, Daniele A, & Albanese A (2012) Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurol, 11, 429-442.
15. Guo Y, Park C, Worth RM, & Rubchinsky LL (2013) Basal ganglia modulation of thalamocortical relay in Parkinson's disease and dystonia. Front Comput Neurosc, 7, 124.
16. Loane C, Wu K, Bain P, Brooks DJ, Piccini P, & Politis M (2013) Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. Neurology, 80, 1850-1855.
17. Brooks DJ (2007) Imaging non-dopaminergic function in Parkinson's disease. Mol Imaging Biol, 9, 217-222.
18. Finn M, Jassen A, Baskin P, & Salamone JD (1997) Tremulous characteristics of the vacuous jaw movements induced by pilocarpine and ventrolateral striatal dopamine depletions. Pharmacol Biochem Behav, 57, 243-249.
19. Gradinaru V, Mogri M, Thompson KR, Henderson JM, & Deisseroth K (2009) Optical deconstruction of parkinsonian neural circuitry. Science, 324, 354-359.
20. Magnin M, Morel A,&JeanmonodD(2000) Single-unit analysis of the pallidum, thalamus and subthalamic nucleus in parkinsonian patients. Neuroscience, 96, 549-564.
21. Marek GJ, Wright RA, Gewirtz JC, & Schoepp DD (2001) A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex. Neuroscience, 105, 379-392.
22. Miner LA, Backstrom JR, Sanders-Bush E, & Sesack SR (2003) Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience, 116, 107-117.
23. Spiros A, Carr R, & Geerts H (2010) Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse. Neuropsychiatr Dis Treat, 6, 589-603.
24. Cragg SJ, Hille CJ,&GreenfieldSA(2000) Dopamine release and uptake dynamics within nonhuman primate striatum in vitro. J Neurosci, 20, 8209-8217.
25. Roberts PD, Spiros A, & Geerts H (2012) Simulations of symptomatic treatments for Alzheimer's disease: Computational analysis of pathology and mechanisms of drug action. Alzheimers Res The, 4, 50.
26. Aznar S, Qian Z, Shah R, Rahbek B, & Knudsen GM (2003) The 5-HT1A serotonin receptor is located on calbindin-and parvalbumin-containing neurons in the rat brain. Brain Res, 959, 58-67.
27. Azmitia EC, Gannon PJ, Kheck NM, & Whitaker-Azmitia PM (1996) Cellular localization of the 5-HT1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology, 14, 35-46.
28. Llinas RR (2000) Mapping brain terrain. Neurobiol Dis, 7, 499-500.
29. Rhodes PA, & Llinas RR (2001) Apical tuft input efficacy in layer 5 pyramidal cells from rat visual cortex. J Physiol, 536, 167-187.
30. Carr DB, Cooper DC, Ulrich SL, Spruston N, & Surmeier DJ (2002) Serotonin receptor activation inhibits sodium current and dendritic excitability in prefrontal cortex via a protein kinase C-dependent mechanism. J Neurosci, 22, 6846-6855.
31. Foehring RC (1996) Serotonin modulates N-and P-type calcium currents in neocortical pyramidal neurons via a membrane-delimited pathway. J Neurophysiol, 75, 648-659.
32. Williams GV, & Goldman-Rakic PS (1995) Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature, 376, 572-575.
33. Brown P, Mazzone P, Oliviero A, Altibrandi MG, Pilato F, Tonali PA,& Di LazzaroV(2004) Effects of stimulation of the subthalamic area on oscillatory pallidal activity in Parkinson's disease. Exp Neurol, 188, 480-490.
34. Brown P, Oliviero A, Mazzone P, Insola A, Tonali P,&Di Lazzaro V (2001) Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson's disease. J Neurosci, 21, 1033-1038.
35. Kapur S, Mizrahi R, & Li M (2005) From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophr Res, 79, 59-68.
36. Falk T, Xie JY, Zhang S, Kennedy J, Bennett J, Yool AJ, & Sherman SJ (2008) Over-expression of the potassium channel Kir2.3 using the dopamine-1 receptor promoter selectively inhibits striatal neurons. Neuroscience, 155, 114-127.
37. Gabel LA, & Nisenbaum ES (1998) Biophysical characterization and functional consequences of a slowly inactivating potassium current in neostriatal neurons. J Neurophysiol, 79, 1989-2002.
38. Grace AA, & Bunney BS (1984) The control of firing pattern in nigral dopamine neurons: Burst firing. J Neurosci, 4, 2877-2890.
39. Grace AA, & Bunney BS (1984) The control of firing pattern in nigral dopamine neurons: Single spike firing. J Neurosci, 4, 2866-2876.
40. Tian L, Karimi M, Loftin SK, Brown CA, Xia H, Xu J, Mach RH, & Perlmutter JS (2012) No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease. PLoS ONE 7, e31439.
41. Odagaki Y, Nakai H, Senokuchi K, Kawamura M, Hamanaka N, Nakamura M, Tomoo K, & Ishida T (1995) Unique binding of a novel synthetic inhibitor, N-[3-[4-[4-(amidinophenoxy)carbonyl]phenyl]-2-methyl-2-propenoyl] -N-allylglycine methanesulfonate, to bovine trypsin, revealed by the crystal structure of the complex. Biochemistry, 34, 12849-12853.
42. Odagaki Y, & Fuxe K (1995) 5-HT1A receptor-mediated activation of high-affinity GTPase in rat hippocampal membranes. Eur J Pharmacol, 288, 385-388.
43. Cocchi D, Locatelli V, Picciolini E, Genazzani AR, &Muller EE (1979) Prolactin-lowering effect of nomifensine in the rat. Proc Soc Exp Biol Med, 162, 38-43.
44. Tang TS, Slow E, Lupu V, Stavrovskaya IG, Sugimori M, Llinas R, Kristal BS, Hayden MR, & Bezprozvanny I (2005) Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc Natl Acad Sci U S A, 102, 2602-2607.
45. Hunter KR, Boakes AJ, Laurence DR, & Stern GM (1970) Monoamine oxidase inhibitors and L-dopa. Br Med, 3, 388.
46. Werneck AL, Rosso AL, & Vincent MB (2009) The use of an antagonist 5-HT2a/c for depression and motor function in Parkinson' disease. Arq Neuropsiquiatr, 67, 407-412.
47. Kalia LV, Brotchie JM,&Fox SH (2013) Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials. Mov Disord, 28, 131-144.
48. Morelli M, Blandini F, Simola N,&Hauser RA (2012) A(2A) Receptor antagonism and dyskinesia in Parkinson's Disease. Parkinsons Di, 2012, 489853.
49. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, & Laruelle M (2000) Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 97, 8104-8109.
50. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, & Berman KF (2002) Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci, 5, 267-271.
51. Ferguson MC, Nayyar T, Deutch AY, & Ansah TA (2010) 5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease. Neuropharmacology, 59, 31-36.
52. Auclair AL, Galinier A, Besnard J, Newman-Tancredi A, & DepoortereR(2007) Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats. Psychopharmacology (Berl), 193, 45-54.
53. Ballanger B, StrafellaAP, van EimerenT, Zurowski M, Rusjan PM, Houle S, & Fox SH (2010) Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol, 67, 416-421.
54. Hesse S, Meyer PM, Strecker K, Barthel H, Wegner F, Oehlwein C, Isaias IU, Schwarz J, & Sabri O (2009) Monoamine transporter availability in Parkinson's disease patients with or without depression. Eur J Nucl Med Mol Imaging 36, 428-435.
55. Navailles S, Benazzouz A, Bioulac B, Gross C, & De Deurwaerdere P (2010) High-frequency stimulation of the subthalamic nucleus and L-3,4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease. J Neurosci, 30, 2356-2364.
56. Guo Y, Rubin JE, McIntyre CC, Vitek JL, & Terman D (2008) Thalamocortical relay fidelity varies across subthalamic nucleus deep brain stimulation protocols in a data-driven computational model. J Neurophysiol, 99, 1477-1492.
57. Besnard J, Ruda GF, Setola V, Abecassis K, Rodriguiz RM, Huang XP, Norval S, Sassano MF, Shin AI, Webster LA, Simeons FR, Stojanovski L, Prat A, Seidah NG, Constam DB, Bickerton GR, Read KD, Wetsel WC, Gilbert IH, Roth BL, & Hopkins AL (2012) Automated design of ligands to polypharmacological profiles. Nature, 492, 215-220.
58. Geerts H (2009) Of mice and men: Bridging the translational disconnect in CNS drug discovery. CNS Drugs, 23, 915-926.